Active, not recruitingPHASE1, PHASE2NCT06550011

Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

Studying Twin-reversed arterial perfusion sequence

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Avirmax Biopharma Inc
Intervention
ABI-110 Low Dose(drug)
Enrollment
18 target
Eligibility
50-89 years · All sexes
Timeline
20242031

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06550011 on ClinicalTrials.gov

Other trials for Twin-reversed arterial perfusion sequence

Additional recruiting or active studies for the same condition.

See all trials for Twin-reversed arterial perfusion sequence

← Back to all trials